Complete Definition of Immunological Correlates of Protection and Clearance of Hepatitis C Virus Infection: A Relevant Pending Task for Vaccine Development

REFERENCES

• Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Davila JA, Morgan RO, Shaib Y, McGlynn KA, El Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372–1380.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
   PubMed Web of Science ®Google Scholar
• Diepolder HM, Zachoval R, Hoffmann RM, Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346(8981):1006–1007.
   PubMed Web of Science ®Google Scholar
• Kaplan DE, Sugimoto K, Newton K, Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology. 2007;132(2):654–666.
   Google Scholar
• Thimme R, Bukh J, Spangenberg HC, Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002;99(24):15661–15668.
   PubMed Web of Science ®Google Scholar
• Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13(1):34–41.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM, The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450–456.
   PubMed Web of Science ®Google Scholar
• Chang KM, Thimme R, Melpolder JJ, Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001;33(1):267–276.
   Web of Science ®Google Scholar
• Lechner F, Gruener NH, Urbani S, CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30(9):2479–2487.
   Google Scholar
• Missale G, Bertoni R, Lamonaca V, Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98(3):706–714.
   PubMed Web of Science ®Google Scholar
• Takaki A, Wiese M, Maertens G, Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578–582.
   PubMed Web of Science ®Google Scholar
• Firbas C, Jilma B, Tauber E, Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 2006;24(20):4343–53.
   PubMed Web of Science ®Google Scholar
• Habersetzer F, Honnet G, Bain C, A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology. 2011;141(3):890–899.
   PubMed Web of Science ®Google Scholar
• Nevens F, Roskams T, van Vlierberghe H, A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology. 2003;38(5):1289–1296.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lajonchere L, Shoukry NH, Gra B, Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepat. 2009;16(3):156–167.
   PubMed Web of Science ®Google Scholar
• Schlaphoff V, Klade CS, Jilma B, Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. Vaccine. 2007;25(37-38):6793–6806.
   Google Scholar
• Castellanos M, Cinza Z, Dorta Z, Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med. 2010;12(1):107–116.
   PubMed Web of Science ®Google Scholar
• Frey SE, Houghton M, Coates S, Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010;28(38):6367–6373.
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T, Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008;134(5):1385–1395.
   PubMed Web of Science ®Google Scholar
• Bailey J. An assessment of the use of chimpanzees in hepatitis C research past, present and future, 2: alternative replacement methods. Altern Lab Anim. 2010;38(6):471–494.
   Google Scholar
• Yu C, Boon D, McDonald SL, Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol. 2010;84(21):11264–11278.
   PubMed Web of Science ®Google Scholar
• Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol. 2010;2010:548280.
   Google Scholar
• Shoukry NH, Grakoui A, Houghton M, Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197(12):1645–1655.
   PubMed Web of Science ®Google Scholar
• Nanda S, Havert MB, Calderon GM, Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS ONE. 2008;3(10):e3442.
   Google Scholar
• Watanabe H, Wells F, Major ME. Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase. J Viral Hepat. 2010;17(4):245–253.
   PubMed Web of Science ®Google Scholar
• Sugitani M, Nishimura S, Mizuno K, Shikata T. Analyses of amino acid sequences in hypervariable region-1 of hepatitis C virus (HCV) in sera from chimpanzees infected three times with the same HCV strain. J Med Primatol. 2010;39(1):1–8.
   Google Scholar
• Bukh J, Thimme R, Meunier JC, Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol. 2008;82(16):8183–8195.
   Google Scholar
• Prince AM, Brotman B, Lee DH, Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis. 2005;192(10):1701–1709.
   Google Scholar
• Barth H, Rybczynska J, Patient R, Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology. 2011;54(4):1135–1148.
   Google Scholar
• Uebelhoer L, Han JH, Callendret B, Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 2008;4(9):e1000143.
   Google Scholar
• Duan H, Struble E, Zhong L, Hepatitis C virus with a naturally occurring single amino-acid substitution in the E2 envelope protein escapes neutralization by naturally-induced and vaccine-induced antibodies. Vaccine. 2010;28(25):4138–4144.
   Google Scholar
• Puig M, Mihalik K, Tilton JC, CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology. 2006;44(3):736–745.
   Google Scholar
• Fuller MJ, Shoukry NH, Gushima T, Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology. 2010;51(2):378–387.
   Google Scholar
• Youn JW, Park SH, Lavillette D, Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42(6):1429–1436.
   PubMed Web of Science ®Google Scholar
• Verstrepen BE, Depla E, Rollier CS, Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis. 2011;204(6):837–844.
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong SH, Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A. 2007;104(20):8427–8432.
   PubMed Web of Science ®Google Scholar
• Youn JW, Hu YW, Tricoche N, Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82(21):10896–10905.
   PubMed Web of Science ®Google Scholar
• Zubkova I, Choi YH, Chang E, T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine. 2009;27(19):2594–2602.
   PubMedGoogle Scholar
• Folgori A, Capone S, Ruggeri L, A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190–197.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ, Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology. 2007;45(3):602–613.
   PubMed Web of Science ®Google Scholar
• Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res. 2010;40(1):69–82.
   Google Scholar
• Tong Y, Zhu Y, Xia X, Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol. 2011,85(6):2793–2802.
   PubMed Web of Science ®Google Scholar
• Washburn ML, Bility MT, Zhang L, A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology. 2011;140(4):1334–1344.
   PubMed Web of Science ®Google Scholar
• Osburn WO, Fisher BE, Dowd KA, Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138(1):315–324.
   PubMed Web of Science ®Google Scholar
• Guobuzaite A, Chokshi S, Balciuniene L, Viral clearance or persistence after acute hepatitis C infection: interim results from a prospective study. Medicina (Kaunas). 2008;44(7):510–520.
   Google Scholar
• Kamal SM, Amin A, Madwar M, Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78(22):12252–12258.
   Google Scholar
• Scognamiglio P, Accapezzato D, Casciaro MA, Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol. 1999;162(11):6681–6689.
   Google Scholar
• Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 2006;69(3):129–141.
   PubMed Web of Science ®Google Scholar
• Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42(1):104–112.
   Google Scholar
• Thurairajah P, Hegazy D, Chokshi S, Hepatitis C virus (HCV)–specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198(12):1749–1755.
   PubMedGoogle Scholar
• Mizukoshi E, Eisenbach C, Edlin BR, Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis. 2008;198(2):203–212.
   Google Scholar
• Rosen HR, Miner C, Sasaki AW, Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35(1):190–198.
   PubMed Web of Science ®Google Scholar
• Neveu B, Debeaupuis E, Echasserieau K, Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology. 2008;48(3):713–722.
   Google Scholar
• Yerly D, Heckerman D, Allen TM, Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol. 2008;82(6):3147–3153.
   Google Scholar
• Wherry EJ, Ha SJ, Kaech SM, Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670–684.
   PubMed Web of Science ®Google Scholar
• Rutebemberwa A, Ray SC, Astemborski J, High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol. 2008;181(12):8215–8225.
   Google Scholar
• Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol. 2008;180(6):3637–3641.
   PubMedGoogle Scholar
• Kasprowicz V, Schulze Zur WJ, Kuntzen T, High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol. 2008;82(6):3154–3160.
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–952.
   PubMed Web of Science ®Google Scholar
• Christie JM, Healey CJ, Watson J, Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol. 1997;110(1):4–8.
   Google Scholar
• Post JJ, Pan Y, Freeman AJ, Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004;189(10):1846–1855.
   PubMed Web of Science ®Google Scholar
• Logvinoff C, Major ME, Oldach D, Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A. 2004;101(27):10149–10154.
   PubMed Web of Science ®Google Scholar
• Steinmann D, Barth H, Gissler B, Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol. 2004;78(17):9030–9040.
   Google Scholar
• Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology. 2009;136(7):2377–2386.
   PubMed Web of Science ®Google Scholar
• Lavillette D, Morice Y, Germanidis G, Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79(10):6023–6034.
   PubMed Web of Science ®Google Scholar
• Sasayama M, Deng L, Kim SR, Ide Y, Shoji I, Hotta H. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin. Kobe J Med Sci. 2010;56(2):E60–E66.
   Google Scholar
• Baumert TF, Wellnitz S, Aono S, Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology. 2000;32(3):610–617.
   Google Scholar
• Pestka JM, Zeisel MB, Blaser E, Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007;104(14):6025–6030.
   PubMed Web of Science ®Google Scholar
• von Hahn T, Yoon JC, Alter H, Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology. 2007;132(2): 667–678.
   Google Scholar
• Haberstroh A, Schnober EK, Zeisel MB, Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 2008;135(5):1719–1728.
   Google Scholar
• Zhang P, Wu CG, Mihalik K, Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A. 2007;104(20):8449–8454.
   Web of Science ®Google Scholar
• Sandrin V, Boulanger P, Penin F, Granier C, Cosset FL, Bartosch B. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J Gen Virol. 2005;86(Pt 12):3189–3199.
   PubMedGoogle Scholar
• Lee S, Varano J, Flexman JP, Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Dis Markers. 2010;28(5):273–280.
   Google Scholar
• Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007;45(3):262–268.
   Google Scholar
• Harvey CE, Post JJ, Palladinetti P, Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74(3):360–369.
   Google Scholar
• Lagging M, Romero AI, Westin J, IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology. 2006;44(6):1617–1625.
   Google Scholar
• Reiberger T, Aberle JH, Kundi M, IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther. 2008;13(8):969–976.
   PubMed Web of Science ®Google Scholar
• Sugimoto R, Enjoji M, Nakamuta M, Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int. 2005;25(2):420–428.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Lutchman GA, Heller T, Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology. 2010;139(1):154–162.
   PubMed Web of Science ®Google Scholar
• Zeremski M, Shu MA, Brown Q, Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16(1): 10–20.
   Google Scholar
• Mizukoshi E, Rehermann B. Immune responses and immunity in hepatitis C virus infection. J Gastroenterol. 2001;36(12):799–808.
   Google Scholar
• Golden-Mason L, Bambha KM, Cheng L, Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C. Hepatology. 2011;54(5): 1559–1569.
   Google Scholar
• Stegmann KA, Bjorkstrom NK, Veber H, Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology. 2010;138(5):1885–1897.
   Google Scholar
• Ahlenstiel G, Edlich B, Hogdal LJ, Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology. 2011;141(4):1231–1239.
   PubMed Web of Science ®Google Scholar
• Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology. 2010;52(5):1581–1589.
   Google Scholar
• Tsubouchi E, Akbar SM, Murakami H, Horiike N, Onji M. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy. Clin Exp Immunol. 2004;137(2):417–423.
   Google Scholar
• Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology. 2004;40(2):335–345.
   Google Scholar
• Dolganiuc A, Chang S, Kodys K, Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006;177(10):6758–6768.
   PubMed Web of Science ®Google Scholar
• Pachiadakis I, Chokshi S, Cooksley H, Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol. 2009;131(3):415–425.
   Google Scholar
• Gowans EJ, Roberts S, Jones K, A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53(4):599–607.
   Google Scholar
• Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology. 2007;46(6):1713–1721.
   PubMedGoogle Scholar
• Kuniholm MH, Kovacs A, Gao X, Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology. 2010;51(5):1514–1522.
   PubMedGoogle Scholar
• McKiernan SM, Hagan R, Curry M, Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology. 2004;40(1):108–114.
   Google Scholar
• Bosi I, Ancora G, Mantovani W, HLA DR13 and HCV vertical infection. Pediatr Res. 2002;51(6):746–749.
   Google Scholar
• Bevilacqua E, Fabris A, Floreano P, Genetic factors in mother-to-child transmission of HCV infection. Virology. 2009;390(1):64–70.
   Google Scholar
• Martinetti M, Pacati I, Cuccia M, Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus. Int J Immunopathol Pharmacol. 2006;19(2):369–378.
   Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105–1109.
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104.
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–1345.
   PubMed Web of Science ®Google Scholar
• Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology. 2011;53(6):1830–1838.
   PubMed Web of Science ®Google Scholar
• Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut. 2011;60(9):1284–1293.
   PubMed Web of Science ®Google Scholar
• Witte K, Gruetz G, Volk HD, Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10(8):702–714.
   PubMed Web of Science ®Google Scholar
• Kutscher S, Bauer T, Dembek C, Sprinzl M, Protzer U. Design of therapeutic vaccines: hepatitis B as an example. Microb Biotechnol. 2011;5(2):270–282.
   Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ, HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659–662.
   PubMed Web of Science ®Google Scholar
• Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10(5):659–672.
   PubMed Web of Science ®Google Scholar
• Ray R, Meyer K, Banerjee A, Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis. 2010;202(6):862–866.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Schuller E, Schlaphoff V, Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine. 2009;27(37):5142–5151.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4(115):115ra1.
   PubMed Web of Science ®Google Scholar
• Dorner M, Horwitz JA, Robbins JB, A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011;474(7350):208–211.
   PubMed Web of Science ®Google Scholar
• Lerat H, Honda M, Beard MR, Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology; 2002,122(2):352–365.
   PubMed Web of Science ®Google Scholar
• Naas T, Ghorbani M, Alvarez-Maya I, Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J Gen Virol. 2005;86(Pt 8):2185–2196.
   PubMedGoogle Scholar
• Mercer DF, Schiller DE, Elliott JF, Hepatitis C virus replication in mice with chimeric human livers. Nat Med. 2001;7(8):927–933.
   PubMed Web of Science ®Google Scholar
• Azuma H, Paulk N, Ranade A, Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol. 2007;25(8):903–910.
   PubMed Web of Science ®Google Scholar
• Griffin S, Trowbridge R, Thommes P, Chimeric GB virus B genomes containing hepatitis C virus p7 are infectious in vivo. J Hepatol. 2008;49(6):908–915.
   Google Scholar
• Yoshida T, Saito A, Iwasaki Y, Characterization of natural killer cells in tamarins: a technical basis for studies of innate immunity. Front Microbiol. 2010;1:128.
   Google Scholar
• Amako Y, Tsukiyama-Kohara K, Katsume A, Pathogenesis of hepatitis C virus infection in Tupaia belangeri. J Virol. 2010;84(1):303–311.
   Web of Science ®Google Scholar
• Haller AA, Lauer GM, King TH, Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25(8):1452–1463.
   Google Scholar
• Sallberg M, Frelin L, Weiland O. DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Expert Opin Biol Ther. 2009;9(7):805–815.
   PubMed Web of Science ®Google Scholar
• Drane D, Maraskovsky E, Gibson R, Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin. 2009;5(3):151–157.
   PubMed Web of Science ®Google Scholar
• Yutani S, Yamada A, Yoshida K, Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007;25(42):7429–7435.
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Shichijo S, Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009;100(10):1935–1942.
   PubMed Web of Science ®Google Scholar